Reports frequently cite nausea, vomiting, and abdominal pain [1]
UK regulatory resource
Men with uncontrolled diabetes, insulin resistance, or metabolic disease should be evaluated carefully before starting peptides, since some peptides may affect appetite, blood sugar, insulin sensitivity, or fluid balance
Peptide therapy dosing, delivery method, and treatment duration must be determined by a licensed medical provider based on individual evaluation and lab work
Probably yes, and heres why - Sex differences in GI sensitivity: Women's stomachs usually empty more slowly than men's
The confusion comes not from the math itself but from the fact that compounded tirzepatide ships in multiple concentrations, and each one requires a different draw volume for the same milligram dose